Orforglipron vs Retatrutide
Editorial comparison of Orforglipron (orforglipron) and Retatrutide (retatrutide). Same drug class context, trial-anchored data, no marketing claims.
Side-by-side
| Dimension | Orforglipron | Retatrutide |
|---|---|---|
| Generic name | orforglipron | retatrutide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA approved | 2026 | — |
| Mechanism | Same target as injectable GLP-1s — the GLP-1 receptor — but a non-peptide small-molecule structure. | Where semaglutide hits one receptor and tirzepatide two, retatrutide adds a third: the glucagon receptor. |
| Dosing | Once-daily oral tablet, titrated upward over several weeks to manage GI side effects. No fasting or water-timing restrictions (unlike Rybelsus). | Investigational. Trial dosing is once-weekly subcutaneous injection with gradual titration; final approved doses are not set. |
| Cost | $149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices. | No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. |
| Pivotal trial result | ~14-15% mean body-weight reduction in Phase 3 (highest dose) | ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2) |
Full Orforglipron review →
First once-daily oral non-peptide GLP-1. Brand-only, launching via LillyDirect at $149/month. No injection, no compounded versions.
Full Retatrutide review →
Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.
Frequently asked
Is Orforglipron or Retatrutide more effective?+
In their pivotal trials, Orforglipron reported ~14-15% mean body-weight reduction in Phase 3 (highest dose), while Retatrutide reported ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2). Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.
How do Orforglipron and Retatrutide compare on cost?+
Orforglipron: $149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices. Insurance coverage will expand through 2026-2027 as formularies add it. Retatrutide: No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.
Can I switch from Orforglipron to Retatrutide?+
Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.
Are Orforglipron and Retatrutide the same drug?+
No. Orforglipron (orforglipron) and Retatrutide (retatrutide) are distinct medications from Eli Lilly and Eli Lilly respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.